Immuron Ltd

IMRN

Company Profile

  • Business description

    Immuron Ltd is a commercial- and clinical-stage biopharmaceutical company focused on the development and commercialization of specifically targeted polyclonal antibodies. Its oral polyclonal antibodies offer delivery within the GI tract and can target viruses or bacteria and neutralize toxins at mucosal surfaces. The Company markets Travelan in Australia, an over-the-counter orally administered passive immunotherapeutic product indicated to reduce the risk of traveler's diarrhea and minor gastrointestinal disorders. Its products include Travelan, ProIBS and Protectyn. Its segments are Research and Development and Hyper-immune products, with Hyper-immune products generating maximum revenue. Australia generates maximum revenue.

  • Contact

    25-37, Chapman Street
    Unit 10
    Blackburn
    MelbourneVIC3130
    AUS

    https://www.immuron.com.au

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2027

    Employees

    8

Stocks News & Analysis

stocks

Chip stock selloff deepens in Asia, extends to Europe and US

The week’s tech stock rout continues despite strong earnings from TSMC and ASML.
stocks

Downgrade for ASX listed fund manager as redemptions pile on

Persistent outflows erode earnings outlook.
stocks

Tesla stock is down nearly 20% this year. Is it a buy ahead of earnings?

Following the rollout of its first autonomous Cybercab, here’s what we expect from Tesla’s earnings report.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,940.40100.001.13%
CAC 407,956.7022.000.28%
DAX 4025,622.61239.990.95%
Dow JONES (US)52,002.41175.28-0.34%
FTSE 10010,881.9041.550.38%
HKSE24,186.83124.110.52%
NASDAQ26,140.03572.99-2.14%
Nikkei 22565,324.29898.341.39%
NZX 50 Index13,753.7379.07-0.57%
S&P 5007,659.4484.62-1.09%
S&P/ASX 2008,806.7087.001.00%
SSE Composite Index3,716.288.810.24%

Market Movers